CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 234 enrolled
Drug / intervention
SURGICEL Powder +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03783039
NCT03783039N/ACompleted

A Prospective, RCT Evaluating the Safety and Hemostatic Effectiveness of SURGICEL Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding During Surgery in Chinese Adult Subjects

Ethicon, LLC·interventional·Posted Dec 20, 2018·Updated Jul 8, 2021

In Brief

A clinical study evaluating SURGICEL Powder and SURGICEL Original for Hemorrhage. Completed, enrolled 234 participants across 6 sites.

Detailed Summary

This is a single blind, randomized, prospective study comparing SURGICEL Powder with SURGICEL Original (control arm) as an adjunct to achieve hemostasis in the control of capillary, venous, and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective during surgery (open, laparoscopic, or thoracoscopic) in Chinese adult subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemorrhage
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedDec 20, 2018
Enrollment StartJan 15, 2019
Primary CompletionDec 3, 2019
Study CompletionMay 6, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.5 years ago

Interventions

SURGICEL Powderdevice

Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Powder, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.

SURGICEL Originaldevice

Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Original, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.